BRIEF-Immix Biopharma Announces 95% Complete Response Rate In Interim Update From Relapsed/Refractory AL Amyloidosis Clinical Trial NEXICART-2

Immix Biopharma, Inc.

Immix Biopharma, Inc.

IMMX

0.00

May 21 (Reuters) - Immix Biopharma Inc IMMX.O:

  • IMMIX BIOPHARMA ANNOUNCES 95% COMPLETE RESPONSE RATE IN INTERIM UPDATE FROM RELAPSED/REFRACTORY AL AMYLOIDOSIS CLINICAL TRIAL NEXICART-2

  • IMMIX BIOPHARMA INC - PLANS TO INITIATE PHASE 3 TRIAL IN NEWLY DIAGNOSED AL AMYLOIDOSIS PATIENTS

  • IMMIX BIOPHARMA, INC: NEXT NEXICART-2 UPDATE EXPECTED LATE SEPTEMBER, 2026

  • IMMIX BIOPHARMA: BY MARCH END 2027, EXPECT TO PRESENT 1-YEAR FOLLOW-UP DATA OF ENROLLED PATIENTS; SEES IT TO DRIVE BLA SUBMISSION, COMMERCIAL LAUNCH

Source text: ID:nGNXQRLX

Further company coverage: IMMX.O


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.